Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients

Michaela G. Cuneo, Angela Szeto, Andrew Schrepf, Ellen M. Kinner, Benjamin I. Schachner, Raisa Ahmed, Premal H. Thaker, Michael Goodheart, David Bender, Steve W. Cole, Philip McCabe, Anil K. Sood, Susan K. Lutgendorf, Armando J Mendez

Research output: Contribution to journalArticle

Abstract

Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. The purpose of this investigation was to examine relationships between endogenous oxytocin, tumor-associated inflammation (interleukin-6), and survival in advanced epithelial ovarian cancer patients. Methods: Tumor microenvironment (ascites) and plasma oxytocin levels were analyzed via ELISA on extracted samples obtained from 79 patients. In vitro models were used to characterize oxytocin and oxytocin receptor expression in four ovarian cancer cell lines and to investigate direct anti-inflammatory effects of oxytocin on tumor cell secretion of interleukin-6. High and variable levels of oxytocin were observed in ascites, up to 200 times greater than in plasma. Higher levels of ascites oxytocin were associated with lower levels of systemic and tumor-associated interleukin-6, an inflammatory cytokine implicated in ovarian tumor progression. Oxytocin also attenuated interleukin-6 secretion from multiple ovarian tumor cell lines in vitro. Higher levels of ascites oxytocin were associated with a significant survival advantage and statistical mediation analyses suggested this effect was partially mediated by interleukin-6. Conclusions: These data identify a previously unacknowledged hormone in the ovarian tumor microenvironment and provide initial evidence that oxytocin has protective effects in ovarian cancer via anti-inflammatory mechanisms. Future studies should examine the therapeutic utility of oxytocin.

Original languageEnglish (US)
Pages (from-to)244-251
Number of pages8
JournalPsychoneuroendocrinology
Volume106
DOIs
StatePublished - Aug 1 2019

Fingerprint

Tumor Microenvironment
Oxytocin
Inflammation
Survival
Interleukin-6
Ascites
Ovarian Neoplasms
Anti-Inflammatory Agents
Neoplasms
Ovarian epithelial cancer
Oxytocin Receptors
Tumor Cell Line

Keywords

  • Ascites
  • interleukin-6
  • Ovarian neoplasms
  • Oxytocin
  • Tumor microenvironment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. / Cuneo, Michaela G.; Szeto, Angela; Schrepf, Andrew; Kinner, Ellen M.; Schachner, Benjamin I.; Ahmed, Raisa; Thaker, Premal H.; Goodheart, Michael; Bender, David; Cole, Steve W.; McCabe, Philip; Sood, Anil K.; Lutgendorf, Susan K.; Mendez, Armando J.

In: Psychoneuroendocrinology, Vol. 106, 01.08.2019, p. 244-251.

Research output: Contribution to journalArticle

Cuneo, MG, Szeto, A, Schrepf, A, Kinner, EM, Schachner, BI, Ahmed, R, Thaker, PH, Goodheart, M, Bender, D, Cole, SW, McCabe, P, Sood, AK, Lutgendorf, SK & Mendez, AJ 2019, 'Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients', Psychoneuroendocrinology, vol. 106, pp. 244-251. https://doi.org/10.1016/j.psyneuen.2019.04.007
Cuneo, Michaela G. ; Szeto, Angela ; Schrepf, Andrew ; Kinner, Ellen M. ; Schachner, Benjamin I. ; Ahmed, Raisa ; Thaker, Premal H. ; Goodheart, Michael ; Bender, David ; Cole, Steve W. ; McCabe, Philip ; Sood, Anil K. ; Lutgendorf, Susan K. ; Mendez, Armando J. / Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. In: Psychoneuroendocrinology. 2019 ; Vol. 106. pp. 244-251.
@article{0eae1dd41854463e8d2bb1e1b8ae5631,
title = "Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients",
abstract = "Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. The purpose of this investigation was to examine relationships between endogenous oxytocin, tumor-associated inflammation (interleukin-6), and survival in advanced epithelial ovarian cancer patients. Methods: Tumor microenvironment (ascites) and plasma oxytocin levels were analyzed via ELISA on extracted samples obtained from 79 patients. In vitro models were used to characterize oxytocin and oxytocin receptor expression in four ovarian cancer cell lines and to investigate direct anti-inflammatory effects of oxytocin on tumor cell secretion of interleukin-6. High and variable levels of oxytocin were observed in ascites, up to 200 times greater than in plasma. Higher levels of ascites oxytocin were associated with lower levels of systemic and tumor-associated interleukin-6, an inflammatory cytokine implicated in ovarian tumor progression. Oxytocin also attenuated interleukin-6 secretion from multiple ovarian tumor cell lines in vitro. Higher levels of ascites oxytocin were associated with a significant survival advantage and statistical mediation analyses suggested this effect was partially mediated by interleukin-6. Conclusions: These data identify a previously unacknowledged hormone in the ovarian tumor microenvironment and provide initial evidence that oxytocin has protective effects in ovarian cancer via anti-inflammatory mechanisms. Future studies should examine the therapeutic utility of oxytocin.",
keywords = "Ascites, interleukin-6, Ovarian neoplasms, Oxytocin, Tumor microenvironment",
author = "Cuneo, {Michaela G.} and Angela Szeto and Andrew Schrepf and Kinner, {Ellen M.} and Schachner, {Benjamin I.} and Raisa Ahmed and Thaker, {Premal H.} and Michael Goodheart and David Bender and Cole, {Steve W.} and Philip McCabe and Sood, {Anil K.} and Lutgendorf, {Susan K.} and Mendez, {Armando J}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.psyneuen.2019.04.007",
language = "English (US)",
volume = "106",
pages = "244--251",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients

AU - Cuneo, Michaela G.

AU - Szeto, Angela

AU - Schrepf, Andrew

AU - Kinner, Ellen M.

AU - Schachner, Benjamin I.

AU - Ahmed, Raisa

AU - Thaker, Premal H.

AU - Goodheart, Michael

AU - Bender, David

AU - Cole, Steve W.

AU - McCabe, Philip

AU - Sood, Anil K.

AU - Lutgendorf, Susan K.

AU - Mendez, Armando J

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. The purpose of this investigation was to examine relationships between endogenous oxytocin, tumor-associated inflammation (interleukin-6), and survival in advanced epithelial ovarian cancer patients. Methods: Tumor microenvironment (ascites) and plasma oxytocin levels were analyzed via ELISA on extracted samples obtained from 79 patients. In vitro models were used to characterize oxytocin and oxytocin receptor expression in four ovarian cancer cell lines and to investigate direct anti-inflammatory effects of oxytocin on tumor cell secretion of interleukin-6. High and variable levels of oxytocin were observed in ascites, up to 200 times greater than in plasma. Higher levels of ascites oxytocin were associated with lower levels of systemic and tumor-associated interleukin-6, an inflammatory cytokine implicated in ovarian tumor progression. Oxytocin also attenuated interleukin-6 secretion from multiple ovarian tumor cell lines in vitro. Higher levels of ascites oxytocin were associated with a significant survival advantage and statistical mediation analyses suggested this effect was partially mediated by interleukin-6. Conclusions: These data identify a previously unacknowledged hormone in the ovarian tumor microenvironment and provide initial evidence that oxytocin has protective effects in ovarian cancer via anti-inflammatory mechanisms. Future studies should examine the therapeutic utility of oxytocin.

AB - Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. The purpose of this investigation was to examine relationships between endogenous oxytocin, tumor-associated inflammation (interleukin-6), and survival in advanced epithelial ovarian cancer patients. Methods: Tumor microenvironment (ascites) and plasma oxytocin levels were analyzed via ELISA on extracted samples obtained from 79 patients. In vitro models were used to characterize oxytocin and oxytocin receptor expression in four ovarian cancer cell lines and to investigate direct anti-inflammatory effects of oxytocin on tumor cell secretion of interleukin-6. High and variable levels of oxytocin were observed in ascites, up to 200 times greater than in plasma. Higher levels of ascites oxytocin were associated with lower levels of systemic and tumor-associated interleukin-6, an inflammatory cytokine implicated in ovarian tumor progression. Oxytocin also attenuated interleukin-6 secretion from multiple ovarian tumor cell lines in vitro. Higher levels of ascites oxytocin were associated with a significant survival advantage and statistical mediation analyses suggested this effect was partially mediated by interleukin-6. Conclusions: These data identify a previously unacknowledged hormone in the ovarian tumor microenvironment and provide initial evidence that oxytocin has protective effects in ovarian cancer via anti-inflammatory mechanisms. Future studies should examine the therapeutic utility of oxytocin.

KW - Ascites

KW - interleukin-6

KW - Ovarian neoplasms

KW - Oxytocin

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85064467108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064467108&partnerID=8YFLogxK

U2 - 10.1016/j.psyneuen.2019.04.007

DO - 10.1016/j.psyneuen.2019.04.007

M3 - Article

C2 - 31005045

AN - SCOPUS:85064467108

VL - 106

SP - 244

EP - 251

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

ER -